Thelansis

  The accelerated integration of novel, patient-specific cellular therapies into clinical practice has been underpinned by advances in tumor immunology, genetic engineering, and cell manufacturing. This progression is exemplified by the therapeutic promise of chimeric antigen receptor (CAR) T-cell therapy, particularly in targeting malignancies that express CD19. While significant clinical benefits have been observed in many patients undergoing such treatments, they are not without risks. Notably, up to one-third of patients experience severe toxicities that are attributed to the activation of robust immune effector mechanisms. The primary adverse events include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome, with CRS being the most severe. CRS is precipitated by the rapid activation of the immune system following CAR T cell infusion. It typically presents with initial symptoms of fever, potential...